#BEGIN_DRUGCARD DB04162

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C9H14N4O8

# Chemical_IUPAC_Name:
5-nitro-6-{[(2S,3R,4R)-2,3,4,5-tetrahydroxypentyl]amino}-1,2,3,4-tetrahydropyrimidine-2,4-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
5-Nitro-6-Ribityl-Amino-2,4(1h,3h)-Pyrimidinedione

# HET_ID:
INI

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C9H14N4O8/c14-2-4(16)6(17)3(15)1-10-7-5(13(20)21)8(18)12-9(19)11-7/h3-4,6,14-17H,1-2H2,(H3,10,11,12,18,19)/t3-,4+,6+/m0/s1

# InChI_Key:
InChIKey=KSKGHNZSCSCHEQ-MRKVFDINSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4162

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
306.2295

# Molecular_Weight_Mono:
306.081163444

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1KYY

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.9

# Predicted_LogS:
-1.6

# Predicted_Water_Solubility:
7.49e+00 g/l

# Primary_Accession_No:
DB04162

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936907

# PubChem_Substance_ID:
46509104

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01887

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H](O)[C@H](O)[C@@H](O)CNC1=C(C(=O)NC(=O)N1)[N+]([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:01 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AE014292

# Drug_Target_1_GenBank_ID_Protein:
23464060

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ribH2

# Drug_Target_1_Gene_Sequence:
>477 bp
ATGAACCAAAGCTGTCCGAACAAGACATCCTTTAAAATCGCATTCATTCAGGCCCGCTGG
CACGCCGACATCGTTGACGAAGCGCGCAAAAGCTTTGTCGCCGAACTGGCCGCAAAGACA
GGTGGCAGCGTCGAGGTAGAGATATTCGACGTGCCGGGTGCATATGAAATTCCCCTTCAC
GCCAAGACATTGGCCAGAACCGGGCGCTATGCAGCCATCGTCGGTGCGGCCTTCGTGATC
GACGGCGGCATCTATCGTCATGATTTCGTGGCGACGGCCGTTATCAACGGCATGATGCAG
GTGCAGCTTGAAACGGAAGTGCCGGTGCTGAGCGTCGTGCTGACGCCGCACCATTTCCAT
GAAAGCAAGGAGCATCACGACTTCTTCCATGCTCATTTCAAGGTGAAGGGCGTGGAAGCG
GCCCATGCCGCCTTGCAGATCGTGAGCGAGCGCAGCCGCATCGCCGCGCTTGTCTGA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
12271122	Paulsen IT, Seshadri R, Nelson KE, Eisen JA, Heidelberg JF, Read TD, Dodson RJ, Umayam L, Brinkac LM, Beanan MJ, Daugherty SC, Deboy RT, Durkin AS, Kolonay JF, Madupu R, Nelson WC, Ayodeji B, Kraul M, Shetty J, Malek J, Van Aken SE, Riedmuller S, Tettelin H, Gill SR, White O, Salzberg SL, Hoover DL, Lindler LE, Halling SM, Boyle SM, Fraser CM: The Brucella suis genome reveals fundamental similarities between animal and plant pathogens and symbionts. Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13148-53. Epub 2002 Sep 23.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3262

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
17356

# Drug_Target_1_Name:
6,7-dimethyl-8-ribityllumazine synthase 2

# Drug_Target_1_Number_of_Residues:
158

# Drug_Target_1_PDB_ID:
1T13

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00885	DMRL_synthase

# Drug_Target_1_Protein_Sequence:
>6,7-dimethyl-8-ribityllumazine synthase 2
MNQSCPNKTSFKIAFIQARWHADIVDEARKSFVAELAAKTGGSVEVEIFDVPGAYEIPLH
AKTLARTGRYAAIVGAAFVIDGGIYRHDFVATAVINGMMQVQLETEVPVLSVVLTPHHFH
ESKEHHDFFHAHFKVKGVEAAHAALQIVSERSRIAALV

# Drug_Target_1_Reaction:
2 6,7-dimethyl-8-(1-D-ribityl)lumazine = riboflavin + 4-(1-D-ribitylamino)-5-amino-2,6-dihydroxypyrimidine

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Riboflavin synthase is a bifunctional enzyme complex catalyzing the formation of riboflavin from 5-amino-6-(1'-D)- ribityl-amino-2,4(1H,3H)-pyrimidinedione and L-3,4-dihydrohy-2- butanone-4-phosphate via 6,7-dimethyl-8-lumazine. The beta subunit catalyzes the condensation of 5-amino-6-(1'-D)-ribityl-amino- 2,4(1H,3H)-pyrimidinedione with L-3,4-dihydrohy-2-butanone-4- phosphate yielding 6,7-dimethyl-8-lumazine

# Drug_Target_1_SwissProt_ID:
P61713

# Drug_Target_1_SwissProt_Name:
RISB2_BRUSU

# Drug_Target_1_Synonyms:
DMRL synthase 2
EC 2.5.1.9
Lumazine synthase 2
Riboflavin synthase 2 beta chain

# Drug_Target_1_Theoretical_pI:
7.14

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
L09228

# Drug_Target_2_GenBank_ID_Protein:
410128

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ribH

# Drug_Target_2_Gene_Sequence:
>465 bp
ATGAATATCATACAAGGAAATTTAGTTGGTACAGGTCTTAAAATCGGAATCGTAGTAGGA
AGATTTAATGATTTTATTACGAGCAAGCTGCTGAGCGGAGCAGAAGATGCGCTGCTCAGA
CATGGCGTAGACACAAATGACATTGATGTGGCTTGGGTTCCAGGCGCATTTGAAATACCG
TTTGCTGCGAAAAAAATGGCGGAAACAAAAAAATATGATGCTATTATCACATTGGGCACT
GTCATCAGAGGCGCAACGACACATTACGATTATGTCTGCAATGAAGCTGCAAAAGGCATC
GCGCAAGCAGCAAACACTACTGGTGTACCTGTCATCTTTGGAATTGTAACAACTGAAAAC
ATCGAACAGGCTATCGAGCGTGCCGGCACAAAAGCGGGCAACAAAGGTGTAGATTGTGCT
GTTTCTGCCATTGAAATGGCAAATTTAAACCGCTCATTTGAATAA

# Drug_Target_2_General_Function:
Coenzyme transport and metabolism

# Drug_Target_2_General_References:
3100522	Ludwig HC, Lottspeich F, Henschen A, Ladenstein R, Bacher A: Heavy riboflavin synthase of Bacillus subtilis. Primary structure of the beta subunit. J Biol Chem. 1987 Jan 25;262(3):1016-21.
3145341	Ladenstein R, Schneider M, Huber R, Bartunik HD, Wilson K, Schott K, Bacher A: Heavy riboflavin synthase from Bacillus subtilis. Crystal structure analysis of the icosahedral beta 60 capsid at 3.3 A resolution. J Mol Biol. 1988 Oct 20;203(4):1045-70.
7473709	Ritsert K, Huber R, Turk D, Ladenstein R, Schmidt-Base K, Bacher A: Studies on the lumazine synthase/riboflavin synthase complex of Bacillus subtilis: crystal structure analysis of reconstituted, icosahedral beta-subunit capsids with bound substrate analogue inhibitor at 2.4 A resolution. J Mol Biol. 1995 Oct 13;253(1):151-67.
7934829	Sorokin A, Zumstein E, Azevedo V, Ehrlich SD, Serror P: The organization of the Bacillus subtilis 168 chromosome region between the spoVA and serA genetic loci, based on sequence data. Mol Microbiol. 1993 Oct;10(2):385-95.
8755892	Graumann P, Schroder K, Schmid R, Marahiel MA: Cold shock stress-induced proteins in Bacillus subtilis. J Bacteriol. 1996 Aug;178(15):4611-9.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3216

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
16287

# Drug_Target_2_Name:
6,7-dimethyl-8-ribityllumazine synthase

# Drug_Target_2_Number_of_Residues:
154

# Drug_Target_2_PDB_ID:
1RVV

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00885	DMRL_synthase

# Drug_Target_2_Protein_Sequence:
>6,7-dimethyl-8-ribityllumazine synthase
MNIIQGNLVGTGLKIGIVVGRFNDFITSKLLSGAEDALLRHGVDTNDIDVAWVPGAFEIP
FAAKKMAETKKYDAIITLGTVIRGATTHYDYVCNEAAKGIAQAANTTGVPVIFGIVTTEN
IEQAIERAGTKAGNKGVDCAVSAIEMANLNRSFE

# Drug_Target_2_Reaction:
2 6,7-dimethyl-8-(1-D-ribityl)lumazine = riboflavin + 4-(1-D-ribitylamino)-5-amino-2,6-dihydroxypyrimidine

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Riboflavin synthase is a bifunctional enzyme complex catalyzing the formation of riboflavin from 5-amino-6-(1'-D)- ribityl-amino-2,4(1H,3H)-pyrimidinedione and L-3,4-dihydrohy-2- butanone-4-phosphate via 6,7-dimethyl-8-lumazine. The beta subunit catalyzes the condensation of 5-amino-6-(1'-D)-ribityl-amino- 2,4(1H,3H)-pyrimidinedione with L-3,4-dihydrohy-2-butanone-4- phosphate yielding 6,7-dimethyl-8-lumazine

# Drug_Target_2_SwissProt_ID:
P11998

# Drug_Target_2_SwissProt_Name:
RISB_BACSU

# Drug_Target_2_Synonyms:
DMRL synthase
EC 2.5.1.9
Lumazine synthase
Riboflavin synthase beta chain

# Drug_Target_2_Theoretical_pI:
5.19

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB04162
